Thyroid Disease and Personality Study

NCT ID: NCT02620085

Last Updated: 2015-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observe the relationship between thyroid function and personality traits

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thyrotoxicosis was the biochemical and physiological manifestations of excess thyroid hormone. The clinical manifestation was palpitation, heat intolerance, hand tremor, and weight loss. The clinical manifestation also included nervous system, including anxiety, tension, irritability, hyperactivity, fatigue, and insomnia.

Where tensions features include restless, short attention span, and the impulse to want to move around. Some patients will progress to a non-specific psychiatric disorders. According to the study, about 10% of patients will occur very frank psychosis, 3, 31% to 69% of patients with depressive symptoms, 61% to 62% of patients with symptoms of anxiety.

Some studies using reliable evaluation tool to evaluate behavioral changes in patients with thyrotoxicosis, such as Clyde emotional scale, multi-faceted personality assessment table (Multiphasic Personality Inventory (MMPI)), or observation of a response time to visual or audio stimulation. After treatment of thyrotoxicosis, most of these indicators have improved, but some indicators were still abnormal after treatment of thyrotoxicosis, such as MMPI and voice response time.

The physiological causes of the changes of these nervous system is not clear. The symptoms was improved after the use of sympathetic inhibitors, so presumably this may correlated with autonomic nervous system disorders.

Thyroid hormone receptors are widely distributed in the brain may also be one of the cause. But there still some other reasons for the changes of neurological symptoms because neurological symptoms may not be back to normal even after thyroid function returned to normal. Autoimmune dysfunction affect brain function may be the most possible reason. Graves' disease is the most common cause of thyrotoxicosis and it is related to autoimmune thyroid antibodies.

Clinically, some patients of Graves' disease may combined with other autoimmune disease, such as Sicca syndrome. The patient may still have nervous personality traits despite normalized thyroid function. Some patients even need long-term use of anti-anxiety medication.

In this study, investigators hope to analyze the personality traits of patients with hyperthyroidism,especially patients of Graves' disease, in Taiwan and to observe the changes during treatment. Investigators also hope to observe the statistical change of other non-thyroid-specific autoimmune index in this thyrotoxicosis patient. After obtaining these results, investigators will evaluate whether to continue to study the hypothesis of affection of brain of thyrotoxic patients by the abnormal autoimmune system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graves' Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Graves' disease

Patient had been diagnosed of Graves' disease and now under euthyroid status

blood sampling

Intervention Type PROCEDURE

blood sampling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sampling

blood sampling

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged between 20 and 85 years
* euthyroid Graves' disease

Exclusion Criteria

* Patients who were not capable to complete the questionnaire due to severe cognitive dysfunction or under education were excluded from this study
Minimum Eligible Age

20 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shyang-Rong Shih, Doctor

Role: STUDY_DIRECTOR

National Taiwan University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shyang-Rong Shih

Taipei, Taiwan, Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shyang-Rong Shih, Doctor

Role: CONTACT

886-972653337

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shyang-Rong Shih

Role: primary

886-972653337

References

Explore related publications, articles, or registry entries linked to this study.

Kathol RG, Delahunt JW. The relationship of anxiety and depression to symptoms of hyperthyroidism using operational criteria. Gen Hosp Psychiatry. 1986 Jan;8(1):23-8. doi: 10.1016/0163-8343(86)90060-5.

Reference Type BACKGROUND
PMID: 3943712 (View on PubMed)

Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J. A psychiatric and neuropsychological study of patients with untreated Graves' disease. Gen Hosp Psychiatry. 1988 Jan;10(1):49-55. doi: 10.1016/0163-8343(88)90084-9.

Reference Type BACKGROUND
PMID: 3345907 (View on PubMed)

BURSTEN B. Psychoses associated with thyrotoxicosis. Arch Gen Psychiatry. 1961 Mar;4:267-73. doi: 10.1001/archpsyc.1961.01710090053007. No abstract available.

Reference Type BACKGROUND
PMID: 13689243 (View on PubMed)

Lee MB, Lee YJ, Yen LL, Lin MH, Lue BH. Reliability and validity of using a Brief Psychiatric Symptom Rating Scale in clinical practice. J Formos Med Assoc. 1990 Dec;89(12):1081-7.

Reference Type BACKGROUND
PMID: 1982678 (View on PubMed)

Lee YC, Wang HP, Chiu HM, Liao SC, Huang SP, Lai YP, Wu MS, Chen MF, Lin JT. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy. J Gastroenterol Hepatol. 2006 May;21(5):798-804. doi: 10.1111/j.1440-1746.2005.04034.x.

Reference Type BACKGROUND
PMID: 16704526 (View on PubMed)

Liao SC, Lee MB, Lee YJ, Huang TS. Hyperleptinemia in subjects with persistent partial posttraumatic stress disorder after a major earthquake. Psychosom Med. 2004 Jan-Feb;66(1):23-8. doi: 10.1097/01.psy.0000106880.22867.0e.

Reference Type BACKGROUND
PMID: 14747634 (View on PubMed)

Chen CA, Liao SC, Wang JK, Chang CI, Chiu IS, Chen YS, Lu CW, Lin MT, Chiu HH, Chiu SN, Hua YC, Lue HC, Wu MH. Quality of life in adults with congenital heart disease: biopsychosocial determinants and sex-related differences. Heart. 2011 Jan;97(1):38-43. doi: 10.1136/hrt.2010.200709. Epub 2010 Oct 26.

Reference Type BACKGROUND
PMID: 20978017 (View on PubMed)

Hsu YC, Liou JM, Liao SC, Yang TH, Wu HT, Hsu WL, Lin HJ, Wang HP, Wu MS. Psychopathology and personality trait in subgroups of functional dyspepsia based on Rome III criteria. Am J Gastroenterol. 2009 Oct;104(10):2534-42. doi: 10.1038/ajg.2009.328. Epub 2009 Jun 16.

Reference Type BACKGROUND
PMID: 19532128 (View on PubMed)

Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull. 1973 Jan;9(1):13-28. No abstract available.

Reference Type BACKGROUND
PMID: 4682398 (View on PubMed)

Liao SC, Lee MB, Lee YJ, Weng T, Shih FY, Ma MH. Association of psychological distress with psychological factors in rescue workers within two months after a major earthquake. J Formos Med Assoc. 2002 Mar;101(3):169-76.

Reference Type BACKGROUND
PMID: 12051011 (View on PubMed)

Lee MB, Rin H, Lin HN, Lee YJ Personality as an effective predictor of outcome for neurotic disorders. Chinese Psychiatry 1990; 4:111-121.

Reference Type BACKGROUND

BARTHOLOMEW AA, MARLEY E. The temporal reliability of the Maudsley personality inventory. J Ment Sci. 1959 Jan;105(438):238-40. doi: 10.1192/bjp.105.438.238. No abstract available.

Reference Type BACKGROUND
PMID: 13641975 (View on PubMed)

EYSENCK HJ. Personality. Annu Rev Psychol. 1952;3:151-74. doi: 10.1146/annurev.ps.03.020152.001055. No abstract available.

Reference Type BACKGROUND
PMID: 12977189 (View on PubMed)

Smilkstein G, Ashworth C, Montano D. Validity and reliability of the family APGAR as a test of family function. J Fam Pract. 1982 Aug;15(2):303-11.

Reference Type BACKGROUND
PMID: 7097168 (View on PubMed)

Schreckenberger MF, Egle UT, Drecker S, Buchholz HG, Weber MM, Bartenstein P, Kahaly GJ. Positron emission tomography reveals correlations between brain metabolism and mood changes in hyperthyroidism. J Clin Endocrinol Metab. 2006 Dec;91(12):4786-91. doi: 10.1210/jc.2006-0573. Epub 2006 Sep 12.

Reference Type BACKGROUND
PMID: 16968792 (View on PubMed)

Jaracz J, Kucharska A, Rajewska-Rager A, Lacka K. Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma. J Endocrinol Invest. 2012 Sep;35(8):760-5. doi: 10.3275/8013. Epub 2011 Oct 6.

Reference Type BACKGROUND
PMID: 21986400 (View on PubMed)

Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010 Feb;123(2):183.e1-9. doi: 10.1016/j.amjmed.2009.06.030.

Reference Type BACKGROUND
PMID: 20103030 (View on PubMed)

Kirshner HS. Hashimoto's encephalopathy: a brief review. Curr Neurol Neurosci Rep. 2014 Sep;14(9):476. doi: 10.1007/s11910-014-0476-2.

Reference Type BACKGROUND
PMID: 25027262 (View on PubMed)

Lin CH, Chang CK, Shih CW, Li HY, Chen KY, Yang WS, Tsai KS, Wang CY, Shih SR. Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves' diseases: a case-control study. Osteoporos Int. 2019 Nov;30(11):2289-2297. doi: 10.1007/s00198-019-05116-1. Epub 2019 Aug 5.

Reference Type DERIVED
PMID: 31384956 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201107013RC

Identifier Type: -

Identifier Source: org_study_id